Ziftomenib: First Approval

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Acute myeloid leukaemia (AML) with NPM1 mutations or KMT2A rearrangements presents significant treatment challenges.
• The menin-KMT2A complex and mutated NPM1 proteins drive leukaemogenesis by increasing transcription of oncogenic genes.
• Targeting the menin interaction offers a potential therapeutic strategy for specific AML subtypes.

Purpose of the Study:

• To summarize the development of ziftomenib, a novel menin inhibitor.
• To highlight the milestones leading to its first regulatory approval.
• To provide an overview of ziftomenib's mechanism of action in NPM1-mutated AML.

Main Methods:

• Review of preclinical and clinical development data for ziftomenib.
• Analysis of the drug's mechanism of action targeting the menin-KMT2A complex.
• Summary of regulatory submission and approval process.

Main Results:

• Ziftomenib demonstrated efficacy in preclinical models and clinical trials for NPM1-mutated AML.
• The drug selectively inhibits the menin-KMT2A interaction, downregulating leukaemogenic gene transcription.
• Ziftomenib received US FDA approval on November 13, 2025, for adults with relapsed or refractory NPM1-mutated AML.

Conclusions:

• Ziftomenib represents a significant advancement in the treatment of relapsed or refractory NPM1-mutated AML.
• Its targeted mechanism offers a new therapeutic option for patients with limited alternatives.
• The approval marks a key milestone in the development of precision medicines for AML.